

Shockwave C2 Aero Coronary IVL Catheter Media Toolkit

Guide Summary

The following guide contains key messages, images and logos for the Shockwave C2 Aero Intravascular Lithotripsy (IVL) Catheter, a next-generation coronary IVL catheter designed to treat a broad spectrum of calcific coronary disease through enhanced deliverability and crossability.^{1,2}

This information can be used to develop external materials like press releases, social media posts or newsletters to educate your physician and patient communities, as well as your internal hospital associates with materials like employee newsletters or emails.

Disclaimer

It is recommended materials use the below disclaimer around important safety information for Shockwave C2 Aero:

US Rx only. Important Safety Information: <https://shockwavemedical.com/isi/coronary-us/>

For individuals outside of the U.S., also add the below disclaimer:

Product availability may vary by country.

About Shockwave C2 Aero Coronary IVL Catheter

- Shockwave C2 Aero is a next-generation coronary IVL catheter designed for improved deliverability, enhanced lesion crossing and new repositioning capabilities for the treatment of calcified coronary artery disease (CAD).^{1,2,3}
- Shockwave C2 Aero provides physicians with greater flexibility and efficiency in treatment strategy by:¹
 - Enhancing deliverability through tight, tortuous arteries via a more flexible shaft, balloon and marker bands.¹
 - Easing entry and crossing of dense calcified deposits with its tapered tip and new hydrophilic coating.²
 - Allowing repositioning within the coronary anatomy to treat additional lesions due to the new balloon material designed for more compact deflation.³
- Shockwave C2 Aero has a working length of 138 centimeters, and features two emitters encased in an integrated balloon that fire simultaneously up to 120 Shockwave pulses, delivering up to 240 Shockwaves.
- To deliver treatment, each Shockwave pulse creates ultrasonic acoustic pressure waves that pass through soft tissue and crack hardened calcium in place, helping re-establish blood flow in the blocked artery.⁴

About IVL

- Intravascular lithotripsy (IVL) is the energy-based generation of ultrasonic acoustic pressure waves for modification, fracture and fragmentation of vascular calcification.

About Coronary Artery Disease (CAD)

- In CAD, progressive buildup of cholesterol deposits gradually narrows the vessels, reducing blood flow to the heart muscle and leading to chest pain (angina) and heart attacks. Over time, cholesterol deposits may accumulate calcium and harden, making them difficult to treat with conventional techniques.
- CAD is the leading cause of death globally, affecting an estimated 315 million people worldwide.⁵
- CAD affects roughly 1 in 20 adults over age 20 in the U.S.^{6,7}

Graphics and Images

Visit [this asset page](#) to access downloadable graphics and images.

Once there, hit “Download all” to download all images, or select one or more images and hit “Download selected” to download select images.

Press release outline

HEADLINE

A concise, compelling statement announcing the key news or milestone

SUBHEAD

A supporting line that provides additional context or impact to the headline

DATELINE + LEAD PARAGRAPH

City, State — Month Day, Year —

A strong opening paragraph summarizing:

- What is being announced
- Why it matters to clinicians, patients or the community
- High-level benefit or impact
level benefit or impact-level benefit or impact

BACKGROUND PARAGRAPH(S)

Short optional paragraphs expanding on:

- The broader challenge or clinical need
- Context for how this news fits into improving patient care, workflow, or outcomes

SUPPORTING DETAILS / KEY HIGHLIGHTS

Bullet points or brief supporting paragraphs that may include:

- Key facts or data points about the product and how it will impact patient care
- Quotes from physicians, hospital leaders, or program managers

QUOTE

A statement from a senior leader emphasizing:

- Organizational commitment to innovation, quality, safety or patient outcomes
- How the announcement aligns with hospital mission or strategic goals

ABOUT THE HOSPITAL

A brief, general “about” section with non-product-specific language appropriate to the institution.

CALL TO ACTION

- Where to find more information
- Contacts for media inquiries

¹ Compared to Shockwave C2+ in simulated use bench testing. Based on feedback from physicians who participated in the Limited Market Release Survey

² Designed with more tapered tip and new hydrophilic coating compared to Shockwave C2+

³ Designed with more flexible material compared to Shockwave C2+

⁴ Kereiakes, D, Virmani, R, Hokama, J. et al. Principles of Intravascular Lithotripsy for Calcific Plaque Modification. J Am Coll Cardiol Intv. 2021 Jun, 14 (12) 1275–1292.

<https://doi.org/10.1016/j.jcin.2021.03.036>

⁵ Stark, B, Johnson, C, Roth, G. GLOBAL PREVALENCE OF CORONARY ARTERY DISEASE: AN UPDATE FROM THE GLOBAL BURDEN OF DISEASE STUDY. JACC. 2024 Apr, 83 (13_Supplement) 2320.

[https://doi.org/10.1016/S0735-1097\(24\)04310-9](https://doi.org/10.1016/S0735-1097(24)04310-9)

⁶ Centers for Disease Control and Prevention. About Coronary Artery Disease (CAD). <https://www.cdc.gov/heart-disease/about/coronary-artery-disease.html>. Last Accessed: March 24, 2025.

⁷ Centers for Disease Control and Prevention. Heart Disease Facts. <https://www.cdc.gov/heart-disease/data-research/facts-stats/index.html>. Last Accessed: March 24, 2025.

SPL 80992 Rev. B